Professor Robert Coleman MBBS, MD, FRCP, FRCPE
YCR Professor of Medical Oncology,
Director of Sheffield Cancer Research Centre and Associate Director of the National Cancer Research Network,
Academic Unit of Clinical Oncology, Weston Park Hospital
Tel: +44 (0)114 226 5213 | Fax: +44 (0)114 226 5364 | Email: email@example.com
Clinical and Translational Research in Breast Cancer
Rob graduated from Kings College Hospital Medical School, University of London and after clinical training in oncology in London and Edinburgh, and completion of a research doctorate (MD) in the field of bone metastases, he took up his current position at Weston Park Hospital in 1991, receiving a personal chair in 1999. Rob now leads a large clinical research team and is the Director of the Sheffield Cancer Research Centre. He is also Associate Director for the National Cancer Research Network. Over the years, Rob has developed a highly successful cancer clinical trials facility based at Weston Park Hospital. This provides the research infrastructure for the North Trent Cancer Research Network and the Experimental Cancer Medicine Centre, with a range of studies from early phase drug development to large phase III randomised trials. Since the mid 1980s Rob’s main research interest has been into cancer induced bone disease, especially with relevance to breast cancer. His research in this area is internationally recognised and has included the development of bone targeted agents in oncology, evaluation of bone biomarkers and the assessment of adverse effects of cancer treatments on bone health.
Rob Coleman has authored or co-authored more than 320 publications of original research and 100 reviews and book chapters. He is on the editorial board of several oncology journals and a reviewer for numerous journals. His research is funded by Cancer Research UK, the National Institute for Health Research, Weston Park Hospital Cancer Charity and the pharmaceutical industry.
1. Smith MR, Saad F, Coleman RE, et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39–46.
2. Coleman RE, Marshall H, Cameron D, et al (2011) on behalf of the AZURE investigators. Breast Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine, 365: 1396–1405.
3. Coleman RE, Banks LM, Girgis SI, et al (2010) on behalf of the Intergroup Exemestane Study (IES) group. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Research and Treatment, 124: 153–161.